Revolution Medicines Stock Forecast

Stock Price Forecast

The 19 analysts that cover Revolution Medicines stock have a consensus rating of "Strong Buy" and an average price target of $140.84, which forecasts a 6.96% increase in the stock price over the next year. The lowest target is $71 and the highest is $215.

Price Target: $140.84 (+6.96%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$71	$140.84	$147	$215
Change	-46.08%	+6.96%	+11.64%	+63.29%

Analyst Ratings

The average analyst rating for Revolution Medicines stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Nov '25	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26
Strong Buy	9	9	8	8	9	8
Buy	9	9	9	9	9	11
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	18	18	17	17	18	19

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Jonathan Chang Leerink Partners	Leerink Partners	Buy Maintains $147 → $171	Buy	Maintains	$147 → $171	+29.87%	Apr 22, 2026
Robert Burns HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $169	Strong Buy	Reiterates	$169	+28.35%	Apr 22, 2026
Laura Prendergast Stifel	Stifel	Strong Buy Reiterates $170 → $215	Strong Buy	Reiterates	$170 → $215	+63.29%	Apr 20, 2026
Ami Fadia Needham	Needham	Strong Buy Maintains $145 → $186	Strong Buy	Maintains	$145 → $186	+41.26%	Apr 20, 2026
Eva Fortea Verdejo Wells Fargo	Wells Fargo	Buy Maintains $144 → $167	Buy	Maintains	$144 → $167	+26.83%	Apr 14, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

54.87M

Revenue Next Year

347.33M

from 54.87M

533.02%

from 54.87M

EPS This Year

-7.88

from -5.95

EPS Next Year

-6.83

from -7.88

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	29.39M	35.38M	11.58M	-	-	54.87M	347.33M
Revenue Growth	-31.62%	20.38%	-67.27%	-	-	-	533.02%
EPS	-2.57	-3.08	-3.86	-3.58	-5.95	-7.88	-6.83
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	23	21

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027
High	262.5M	939.7M
Avg	54.9M	347.3M
Low	n/a	130.1M

Revenue Growth

Revenue Growth	2026	2027
High	-	1,612.5%
Avg	-	533.0%
Low	-	137.0%

EPS Forecast

EPS	2026	2027
High	-6.14	-3.37
Avg	-7.88	-6.83
Low	-8.21	-8.27

EPS Growth

EPS Growth	2026	2027
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.